Considering its multiple metabolic benefits, several clinical trials have been registered to evaluate the therapeutic efficacy of human FGF21 analogues (LY2405319, PF‐05231023, PF‐05231023, BMS‐986036) for the treatment of T2DM, dyslipidaemia and NAFLD, and positive results have been achieved.11 This evidence concerns the gene FGF21 and type 2 diabetes mellitus.